Tissue immersion lymphocyte characteristics predict the survival of patients with early/mid-stage liver cancer BMC Medicine。

Title: Tissue-intoting lymphocytes Signatures predictors survival in patients with early/intermediate stage hepatocellular carcinoma
Journal:
Meng-Xin Tian†, Wei-Ren Liu† Han Wang†, Yu-Fu Zhou†, Lei Jin, Xi-Fei Jiang, Chen-Yang Tao, Zheng Tang, Pei-Yun Zhou, Yuan, Wei-Feng Qu, Zhen-Bin Ding, Yuan-Fei Peng, Zhi Dai, Shuang-Qiu Jian, Jian Zhou, Wan Yee Lau, Jia Fan and Published time
06 Jun, 2019
: 10.1186/s12916-019-13 41-6
Original Link:
WeChat Link:
Hepatocellular Liver Cancer (hepatocellular liver cancer) is a common malignant tumor with more than 70,000 annual deaths worldwide. Its clinical prognostication is not only related to tumor itself and potential liver disease, but also closely related to tumor heterogeneity. At present, the prognosis assessment for liver cancer patients depends on traditional indicators such as tumor number, diameter, vascular invasion and lymph node metastasis. The study points out that liver cancer is a very heterogeneous tumor. The clinical prognosis may vary in liver cancer patients in the same tumor stage. Therefore, how to explore novel prediction indicators from tumor micro-environment will help to develop individual postoperative management plan for liver cancer patients and promote their long-term survival.recently, Professor Shi Yinghong of the Institute of Liver Cancer at Sun Yat-sen Hospital, affiliated with Fudan University, published an article on
called "Tissue-Intoting Lymphocytes Signature Predictors In Patients Early with/Intermediate Stage Hepatocellular Carcinoma". The authors tested 28 immune characteristics of liver cancer in 352 liver cancer tissue samples (training sets) using immunologic tissue chemistry. According to LASSO Cox, five immune characteristics were selected and a new tissue-related immune characteristics (tissue-related immune signature, TRIS) score was established, including CD3intratumoral (T), CD27T, CD68peritumoral (P), CD103T, and PD1T.
single-factor and multi-factor analysis showed that TRIS score, GGT, tumor diameter and tumor differentiation were independent prognostic factors in patients with early/medium-term liver cancer. Based on this, the authors combined the above four indicators to construct an individualized immunoclinical prognostic index model (immune clinical prognostic index, ICPI) for liver cancer patients.
to further verify the reliability of the model, the authors used TRIS scores in 393 separate liver cancer queues (verification sets). The C-indexes of the training and validation sets are 0.691 (95%CI, 0.642-0.739) and 0.686 (95% CI, 0.637-0.735), respectively. The ROC curve analysis shows that the predictive ability of ICPI models in training sets and validation sets is better than that of okuda, CLIP, LCSGJ and BCLC in 7 traditional liver cancer stage systems. Based on the cutoff values of 58.5 and 86.2, the authors divided the queue into three subgroups (Score 1, Score 2, and Score 3). The homogeneity test and correction AIC statistical analysis proved that the homogeneity and AIC of each sub-group were better than that of the other 7 liver cancer stations. Similarly, the results were further validated in the training set. Therefore, the TRIS score for liver cancer may supplement the shortcomings of traditional clinical pathological indicators in prognostic prediction. The ICPI model may provide better prognostic prediction in early/mid-stage liver cancer patients than traditional liver cancer stage systems.。 Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/intermediate HCC.。 Twenty-eight immune features were immunohistochemically examined on 352 HCC specimens. The LASSO Cox regression model was used to construct a five-feature-based TRIS. The univariate and multivariate Cox analyses were performed. Based on independent predictors, the immune-clinical prognostic index (ICPI) was established. Performance assessment was measured with C-index and compared with seven traditional staging systems. The independent validation cohort (n = 393) was included to validate the model.。 By using the LASSO method, the TRIS were constructed on the basis of five immune features, CD3intratumoral (T), CD27T, CD68peritumoral (P), CD103T, and PD1T. Multivariate Cox analysis showed that the TRIS was an independent prognostic predictor. In the training cohort, γ-glutamyl transferase, tumor diameter, tumor differentiation, and TRIS were incorporated into the ICPI. The ICPI presented satisfactory discrimination ability, with C-index values of 0.691 and 0.686 in the training and validation cohorts, respectively. Compared with seven conventional staging systems (C-index, training cohort, 0.548–0.597; validation cohort, 0.519–0.610), the ICPI exhibited better performance for early/intermediate-stage HCCs. Further, the patients were categorized into three subgroups with X-tile software, and the stratified ICPI presented a superior corrected Akaike information criterion and homogeneity in both cohorts.。 Our ICPI was a useful and reliable prognostic tool which may offer good individualized prediction capability for HCC patients with early/intermediate stage.。 is the flagship medical journal of the BMC series. An open access, open peer-reviewed general medical journal, BMC Medicinepublishes outstanding and influential research in all areas of clinical practice, translational medicine, medical and health advances, public health, global health, policy, and general topics of interest to the biomedical and sociomedical professional communities. We also publish stimulating debates and reviews as well as unique forum articles and concise tutorials.
(Source: Science.com)